Book a Call
MDside
Book a Call

GHK-Cu: four decades of papers, few trials

  • MDside
  • October 9, 2026

Key points

  • In diabetic ulcers, a GHK-Cu gel was associated with 98.5% vs 60.8% median closure (1994) [1].
  • In venous ulcers (86 patients), 0.4% GHK-Cu was no better than placebo [2].
  • After CO2 laser (13 patients), there was no objective benefit, only higher satisfaction [3].
  • We found no human trials of injectable GHK-Cu. FDA will consult its advisory committee on GHK-Cu before the end of February 2027 [6][8].

US status (October 2026): For GHK-Cu, the route decides the answer: non-injectable GHK-Cu is being returned to 503A Category 1, while injectable GHK-Cu has no pathway and FDA has flagged an immunogenicity risk. MDside uses topical only.

Four decades of papers have produced a handful of small topical trials with mixed results and no human trial of the injectable form. That gap is the whole story for a clinic deciding what to offer.

GHK-Cu moved from cosmetics to the syringe

GHK-Cu is a tripeptide (glycyl-histidyl-lysine) bound to copper, found in human plasma. It has been studied for decades for its role in wound healing and skin [4]. In recent years it moved from creams to injectable vials, with systemic “rejuvenation” claims.

Topical trials give mixed results

  • Diabetic ulcers (1994): a GHK-Cu gel was associated with median area closure of 98.5% vs 60.8% with vehicle [1].
  • Venous ulcers (1992): 86 patients. 0.4% copper tripeptide was no better than placebo, and silver sulfadiazine was superior [2].
  • Skin after CO2 laser (2006): 13 patients. No objective benefit, only higher subjective satisfaction [3].

A 2026 systematic review of GHK-Cu with microneedling concluded that “clinical literature in humans remains thin and fragmented” and that no adequately powered trials exist for that route [5].

  • 86: patients in the venous-ulcer trial, negative [2]
  • 13: patients after laser, no objective benefit [3]
  • 0: human trials of injectable GHK-Cu found [8]

One group wrote much of the literature

One of the most cited GHK-Cu reviews (2018) has Loren Pickart as first author, affiliated with a cosmetics company (“R&D Skin Biology”), and declares no conflict of interest [4]. According to the 2026 systematic review, about 35% of the primary GHK-Cu literature includes Pickart or Anna Margolina (Skin Biology) as authors [5]. Weigh that literature with this in mind.

FDA split the routes in 2026

FDA treats the routes separately. Non-injectable GHK-Cu returned to Category 1 (substances under evaluation) in May 2026, and the agency announced it will consult its Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 on its potential inclusion on the 503A list [6]. The nomination for injectable GHK-Cu was withdrawn, and FDA keeps it on its list of nominated-and-withdrawn substances with potential safety risks, such as immunogenicity [7].

The evidence for GHK-Cu on skin is mixed and small [1][2][3]. For the injectable route we found no human trials, and FDA notes that human data to inform its safety are limited [7][8].

The supporters’ case rests on the topical route

Topical GHK-Cu has at least one positive trial in diabetic ulcers (98.5% vs 60.8% closure) [1]. In 2026 FDA returned the non-injectable form to Category 1, the list of substances that may be used while under evaluation [6]. The real debate is about the injectable route. The peptide itself is a separate question.

What this means for your clinic

If you offer GHK-Cu, keep it topical and source it from a 503A pharmacy compounding under FDA’s interim policy. See 503A vs 503B sourcing and the supplier diligence checklist. Injectable vials sold as “research use only” sit outside that pathway.

References

  1. Mulder GD, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-69. PMID 17147644. Link
  2. Bishop JB, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7. PMID 1495150. Link
  3. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. PMID 16847171. Link
  4. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7). PMID 29986520. Link
  5. Najafi N, et al. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9(3):269-293. PMID 42787770. Link
  6. U.S. Food and Drug Administration. Interim policy on compounding using bulk drug substances under section 503A: categories (updated 14 May 2026). Link
  7. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Link
  8. ClinicalTrials.gov. API v2 search: “GHK-Cu” and “GHK” (no studies of injectable GHK-Cu; topical or transdermal studies only). Supplementary PubMed search found no clinical trials of injectable GHK-Cu. Accessed 9 October 2026. Link

This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.

Share this article with a friend

Medical direction. Victor D. Cruz, MD, Systems Medical Director, licensed in Florida (ME117105) and New York, directs structure, corporate practice of medicine, delegation and good faith exams. This states who carries clinical responsibility for this subject area. It is not a page-level review: pages that have been reviewed name the reviewer and show the date. How this site is written and checked.